source
- GSK launches $2.5 billion restructuring plan to fund late-stage pipeline and offset upcoming HIV drug patent lossGSK reported $2.4 billion in impairment charges for the second quarter and unveiled a three‑year restructuring designed to save roughly $2.5 billion. The company says the savings will be redirecte…
- GSK CEO outlines £1.9bn cost-saving drive and aims to launch 20 Phase 3 trials by year-endGSK chief executive Luke Miels presented a three‑year plan to make the company more agile and generate significant cost efficiencies. The strategy targets £1.9 billion in annual savings by 2029, wi…